Abstract
Programmed death ligand-1 (PD-L1) is highly expressed on most tumor cells, and it inte-racts with programmed death-1 (PD-1) on the surface of immune cells, which mainly inhibits T cell proliferation and plays an important role in tumor immune escape. The studies find that PD-1/PD-L1 pathway can promote tumor cell glycolysis and epithelial-mesenchymal transition, and can induce PD-L1 expression on macrophages and enhance immunosuppression in tumor microenvironment. Therefore, PD-1/PD-L1 is considered to be an important immunoassay point, and a series of anti-PD-1 and PD-L1 antibodies, such as pembrolizumab, nivolumab, atezolizumab, durvalumab and avelumab, have clinically shown good effects. Further understanding of its mechanism may provide new ideas for the treatment of malignant tumors such as lung tumors. Key words: Tumor escape; Immunotherapy; PD-1/PD-L1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
